Phio Pharmaceuticals Corp (PHIO) - רווח נקי למניה (EPS TTM)

Patents for INTASYL and strict FDA oversight create significant barriers, as confirmed by the annual EPS TTM snapshot, where the value -1.26 determines this level. The stability of cold chain logistics ensures the integrity of the therapy. High demand in immuno-oncology and the potential for partnerships with industry behemoths open broad market prospects for Phio Pharmaceuticals (PHIO).

For Phio Pharmaceuticals (PHIO), which develops RNA interference through scientific partnerships, this indicator serves as a measure of research capitalization efficiency. The metric is calculated as the ratio of total annual net income to the total number of shares. Analyzing the 12-month net income per share chart allows for the exclusion of the impact of share issuances. This price action reflects the real yield of each share, while a decline in the indicator signals risks of investment capital freezing.